Plenvu powder for oral solution
- Name:
Plenvu powder for oral solution
- Company:
Norgine Limited
- Active Ingredients:
Ascorbic acid, Macrogol 3350, Potassium Chloride, Sodium Ascorbate, Sodium Chloride, Sodium sulfate anhydrous
- Legal Category:
Product subject to medical prescription which may be renewed (B)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 05/11/20

XPIL
Package leaflet: Information for the patient
Package leaflet: Information for the patient
1. What Plenvu is and what it is used for
1. What Plenvu is and what it is used for
2. What you need to know before you take Plenvu
2. What you need to know before you take Plenvu
3. How to take Plenvu
3. How to take Plenvu
4. Possible side effects
4. Possible side effects
5. How to store Plenvu
5. How to store Plenvu
6. Contents of the pack and other information
6. Contents of the pack and other information
Click on this link to Download PDF directly
Norgine Limited

Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 5 November 2020 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
The following section shave been updated:
section 4.4:
Ischaemic colitis
Post-marketing cases of ischaemic colitis, including serious, have been reported in patients treated with macrogol for bowel preparation. Macrogol should be used with caution in patients with known risk factors for ischaemic colitis or in case of concomitant use of stimulant laxatives (such as bisacodyl or sodium picosulfate). Patients presenting with sudden abdominal pain, rectal bleeding or other symptoms of ischaemic colitis should be evaluated promptly.
Section 4.8:
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the HPRA Pharmacovigilance Website: www.hpra.ie.
section 10:
3 November 2020
Updated on 5 November 2020 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
- Change to other sources of information section
Free text change information supplied by the pharmaceutical company
The following sections have been updated:
Section 2:
If you experience sudden abdominal pain or rectal bleeding when taking PLENVU for bowel preparation, contact your doctor or seek medical advice immediately.
Section 4:
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via HPRA Pharmacovigilance Website: www.hpra.ie.
By reporting side effects you can help provide more information on the safety of this medicine.
This leaflet was last revised in November 2020
Other sources of information
If you need the information on this leaflet in an alternative format, such as large print, please ring 00 44 1895 826 606.
Updated on 20 February 2020 SPC
Reasons for updating
- Change to section 6.4 - Special precautions for storage
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
6.4 Special precautions for storage
Sachets: Store below 30oCDo not store above 25°C
Reconstituted solutions: Keep prepared solutions below 25°C and drink it within 24 hours. The solutions may be stored in a refrigerator. The solutions must be covered.
10. DATE OF REVISION OF THE TEXT
01 December 201719th February 2020
Updated on 20 February 2020 PIL
Reasons for updating
- Change to section 5 - how to store or dispose
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
5. How to store Plenvu
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the sachets and carton, after “EXP”. The expiry date refers to the last day of that month.
Please note that the expiry dates may be different for each of the sachets and carton.
Prior to opening do not store above 25°C.
Keep prepared solutions below 25°C and drink it within 24 hours. The solutions may be stored in a refrigerator. The solutions must be covered.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
This leaflet was last revised in 02/2020
Updated on 11 November 2019 SPC
Reasons for updating
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 11 November 2019 PIL
Reasons for updating
- Change to section 5 - how to store or dispose
Updated on 5 April 2019 PIL
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 5 April 2019 SPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 7 March 2018 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 6 March 2018 PIL
Reasons for updating
- New PIL for new product